Tuesday, September 30, 2014
Monday, September 29, 2014
Well, last week I went over some of the cool things one could/find from iOS 8.
I must admit that I wasn't too crazy about how it was delivered. I was in Tampa getting ready for a JADA Live Event (the Journal of the American Dental Association). We had dinner as a team and when I returned to my hotel room, I discovered that my iPad had downloaded the update and was ready to install.
What I didn't realize was how long it would take to get the update installed & ready to use. My iPad is my alarm clock on the road and I couldn't go to sleep until I was *sure* the iPad was ready. so, needless to say I couldn't go to sleep until I was done with the update.
Now comes word that the update has been causing some problems for those that jumped right on the bandwagon (like me). While I have not had any problems at all, it seems that other folks have had problems galore. In order to rectify these problems, Apple quickly pushed out a "fix" update called iOS 8.0.1, but it also caused some problems. In fact, the update caused some serious problems with the flagship products it was supposed to feature (meaning iPhone 6 and 6 Plus users). This info is directly from Apple & discusses how *another* update is needed to fix a problem that rendered some 6 and 6 Plus phones incapable of making phone calls. That's right. The update turned the brand new iPhones into... iPods... very expensive iPods. Oh boy...
Supposedly this problem would be fixed by patch iOS 8.0.2
Now granted all upgrades can be fraught with compatibility issues... but on the newest hardware? Somewhere the soul of Mr. Jobs is spinning...
Friday, September 26, 2014
There have been more than a few questions circulating around the industry regarding the recent purchase of Nobel Biocare by Danaher. As a huge player in the global market for dental implants, Nobel users want to make sure things will continue on their current path of innovation & support. Here is a press release from the company letting customers know what to expect as the transition happens:
Dear Nobel Biocare Customer,
Perhaps you are aware of the exciting news announced last week where Nobel Biocare has entered into a definitive agreement with Danaher whereby Danaher has made a tender offer for all publicly traded shares of Nobel Biocare. With the addition of Nobel Biocare, Danaher's dental platform would be the largest consumable and equipment player in the dental industry with sales approaching 3 billion USD.
Upon completion of the purchase, Nobel Biocare will continue to operate as a stand-alone company and a cornerstone within Danaher's dental platform maintaining our own brand identity, production sites and our headquarters in Switzerland. Our US and Canadian based operations will continue to be served from Yorba Linda, California and Toronto, Ontario, with our existing management teams. As a valued customer you should expect no change in our relationship, service level, local representative support or our dedication to help you treat more patients better with our superior products and services.
In fact, Danaher will continue to invest in their dental platform. According to Henk van Duijnhoven, Senior Vice President of Danaher Dental, "The Danaher dental platform will continue to invest in a wide range of dental technologies and innovations to better serve our customers. Bringing Nobel Biocare's deep expertise in implant dentistry, digital prosthetics and software together with our extensive knowledge in 3D imaging, intraoral scanning and digital restorative solutions will further enable us to optimize and integrate workflows. This will lead to better clinical outcomes, shorter treatment times and fewer office visits to the benefit of patients and dental practitioners."
As a pioneer and world leader in the field of innovative implant-based dental restorations, we hope to further strengthen our relationship with you and look forward to this promising next chapter and the exciting possibilities to come. Should you have any questions please don't hesitate to contact me directly at firstname.lastname@example.org.
Thank you for your continued support and partnership.
Thursday, September 25, 2014
Wayne A. Aldredge, DMD, President-elect: A member of the AAP since 1995, Dr. Aldredge has nearly 20 years of professional dentistry experience, first honing his general dentistry skills as an army captain at the U.S. Military Academy at West Point. In addition to his current work as a Holmdel, N.J., periodontist, Dr. Aldredge is a clinical assistant professor at Stony Brook University’s Department of Periodontics and Dental Implantology. A diplomate of the American Board of Periodontology, he is a dental graduate of the University of Medicine and Dentistry of New Jersey, and he obtained a post-graduate degree in periodontology at the State University of New York at Stony Brook.
The American Academy of Periodontology (AAP) represents nearly 8,000 periodontists—specialists in the prevention, diagnosis, and treatment of inflammatory diseases affecting the gums and supporting structures of the teeth, and in the placement of dental implants. Periodontics is one of the nine dental specialties recognized by the American Dental Association.
Wednesday, September 24, 2014
Here's an interesting story from the world of dentistry and one of the industry's favorite products, toothpaste.
For consumers, the name "Crest" has got to be either the most recognized or the second most recognized toothpaste brand on the US market. The brand has been around for longer than we've been alive and has always carried a very high degree of consumer confidence.
Recently it seems that the toothpaste industry has had a couple of less than stellar news items. The first was concerns over the chemical "Triclosan" that has been in Colgate products for a while. This issue does not affect Crest users at all. If you would like more info, you can read about it on the Crest website.
The second item that hit the news does deal with Crest. While it doesn't deal with any type of active chemical ingredient, it does deal with a component of some products.
It seems that Crest places small polyethylene microbeads in some of their toothpastes. These beads, which are considered as a food additive by the FDA, are used to help scrub the teeth clean while you brush. There is no concern about the chemical polyethylene, the concern from dentists has to do with the fact that the beads have the potential to become lodged somewhere between the tooth and gum which might create a foreign body reaction.
This potential exists because the microbeads will not dissolve in the mouth. Thus, while I've never heard of a foreign body reaction due to these, the potential does exist.
Once Crest heard of the concern from dentists, they announced they will remove them from the products in which they are found. The company anticipates all supplies will be polyethylene free by 2016.
For a nice overview written for patients, take a look at this article from Foxnews.com
For a look at this issue for dental professionals, my writing home Dental Products Report has a nice article dealing with it.
Tuesday, September 23, 2014
Thursday, September 18, 2014
With my beloved Royals trying hard to make the playoffs, its hard to blog and be at the stadium all at the same time.
To that end, another short post today, but well worth the link.
If you are thinking about updating to a new iPhone, here are some great reasons to love the new iOS.
Check out the story by PC Mag.com
Wednesday, September 17, 2014
Tuesday, September 16, 2014
World leader in innovative implant-based dental restorations will be a cornerstone of Danaher’s global dental business
CHARLOTTE, N.C. — (September 15, 2014) Danaher Corporation announced today that it has entered into a definitive transaction agreement to acquire Nobel Biocare Holding AG, the world leader in implant dentistry. Over the past 40 years, Nobel Biocare has established itself as a pioneer in nearly every aspect of implant dentistry — from PI Brânemark’s discovery of osseointegration, to Procera digital prosthetic solutions and treating fully edentulous patients. In doing so, Nobel Biocare has dramatically changed the lives of millions of patients. Implants and prosthetics are one of the most exciting categories in dentistry today, offering a unique opportunity for dental professionals to deliver long-term solutions to women and men who desire a smile that is both beautiful and functional. With the ways in which technology and materials science continue to shape the implant dentistry workflow, bringing Nobel Biocare to the dental platform upholds Danaher’s commitment to be a world leader in dentistry.
Nobel Biocare will be a cornerstone of the dental platform. With the addition of Nobel Biocare, Danaher will be the strongest consumable and equipment player in the dental industry, with sales approaching $3 billion. Dental implants is a $3.5 billion market with attractive long term growth drivers, including an aging population, growing income in high growth markets and low penetration rates of dental implants in most geographies today. With this acquisition, Danaher will have an unmatched position in dental implants with Nobel Biocare in the premium segment and the Implant Direct joint venture in the value segment; the company plans to further invest in both these segments. Nobel Biocare will operate as a stand-alone company within Danaher’s dental platform, maintaining its own brand and identity. Implant Direct will remain as a stand- alone joint venture with no change in its go to market strategy.
“We will continue to invest in a wide range of dental technologies and innovations to better serve our customers. Bringing Nobel Biocare’s deep expertise in implant dentistry, digital prosthetics and software solutions together with our extensive knowledge in 3D imaging, intraoral scanning and digital restorative solutions will further enable us to optimize and integrate workflows. This will lead to better clinical outcomes, shorter treatment times and fewer office visits to the benefit of patients and dental practitioners,” said Henk van Duijnhoven, Senior Vice President of Danaher’s dental platform. “This combination will further support our business strategy and position our dental business for future growth.”
Danaher’s dental platform reaches 99% of all dental practices through an extensive network of dealer partners as well as direct sales. It will continue its strategy of working closely with its highly valued distribution partners as well as direct sales to maximize market access for all its brands.
“Nobel Biocare’s leadership team has done an outstanding job creating a strong platform for future growth over the last couple of years,” van Duijnhoven added. “Our team is excited to work with CEO Richard Laube and the Nobel Biocare team to build on their efforts toward
continued innovation, growth and business improvement. We look forward to welcoming all Nobel Biocare’s associates, customers and key opinion leaders to the Danaher team.”
About the Danaher Dental Platform:
The Danaher Dental Platform is a global portfolio of leading dental brands that share common values of Trust, Experience, Choices, Quality and Smart Innovation. Brands include KaVo, Kerr, Kerr Total Care, Pentron, Axis|Sybron Endo, Orascoptic, Pelton & Crane, Marus, Gendex, DEXIS, Instrumentarium, SOREDEX, i-CAT, NOMAD, DUX Dental and Ormco. With over 500 years of combined experience and proven solutions, Danaher’s dental platform uniquely serves 99% of all dental
practices. Visit www.kavokerrgroup.com for more information.
Monday, September 15, 2014
Friday, September 12, 2014
The increasing amount of memory just amazes & thrills me. 512GB in a memory card? Incredible!
Here are the details from San Disk:
With write speeds up to 90 MB/s** and recording at the UHS Speed Class 3 (U3)** rating, our most powerful, highest capacity UHS-I SD memory card enables your DSLR, advanced digital or HD video camera** to deliver high resolution, real-world color and stutter-free video. Transfer speeds up to 95 MB/s ensure that your data moves fast for a more efficient post-production workflow.
Shot speeds up to 90MB/s; transfer speeds up to 95 MB/s**
Engineered to capture 4K Ultra High Definition**
Up to 512GB** capacity for uninterrupted video capture at super-fast UHS Speed Class 3 (U3)**
Built for and tested in harsh conditions; temperature proof, water proof, shock proof, and x-ray proof**
Limited lifetime warranty**
-Posted using BlogPress from my iPad
Thursday, September 11, 2014
Hygienists the world over are smiling this morning as Brasseler announces their new Ultrasonic Scaler Inserts. Read on for all the details from the press release I received...
24 Ergonomic Scaler Inserts Available for Greater Patient Comfort
and Practice Efficiency
SAVANNAH, GA (September 10, 2014) – Brasseler USA®, a leading manufacturer of quality instrumentation, is pleased to introduce a wide variety of new ultrasonic scaler inserts for its popular HygienePro™ family of products for the dental hygiene professional.
HygienePro™ Ultrasonic Scaler Inserts are ergonomically designed to substantially reduce user fatigue while increasing patient comfort. Available in both hard and soft grips, the new inserts are extremely versatile and easy to implement. HygienePro Ultrasonic Scaler Inserts are compatible with all magnetostrictive devices.
Ergonomic grip designs feature a textured, non-slip surface that significantly reduces hand and wrist fatigue for enhanced user comfort and control. Moreover, HygienePro Ultrasonic Scaler Inserts are equipped with a patented laminate solder joint ensuring extraordinary durability, consistent spray, and an even vibration.
A wide variety of tip designs are available in both 25K and 30K frequency options to suit each user’s unique individual requirements:
- •Universal – the universal tip design is available in slotted and direct focus water delivery options
- •Slim – the slim tip design is also available in slotted and direct focus water delivery options
- •Triple Bend – the triple bend tip design is available exclusively in slotted water delivery option
- •Beaver Tail – the beaver tail tip design is available exclusively in slotted water delivery option
For more information about the HygienePro Ultrasonic Scaler Inserts, please visit www.BrasselerUSA.com or call 800-841-4522.
About Brasseler USA®
Brasseler USA® is a leading ISO Certified healthcare company, providing quality instrumentation to healthcare professionals for use in restorative dentistry, endodontics, oral surgery and oral hygiene. Over the past 35 years, Brasseler USA
has developed a reputation as an innovative market leader in diamonds, carbides, polishers, endodontics, hand instruments and handpieces. Today, Brasseler USA offers the most comprehensive assortment of instruments and power systems under one brand in the world. For more information, please visit www.BrasselerUSA.com.
Wednesday, September 10, 2014
Monday, September 8, 2014
- Weighing in at only 33 grams, the slim, ergonomic design of the Forza V3 handpiece provides excellent access while reducing hand fatigue.
- Dual LED fiber optics deliver clearer vision and maximum visibility.
- A control unit holder provides multiple mounting options and a sliding bracket feature that allows the unit to be conveniently stored away when not in use.
- Easy power and water adjustment knobs on a simple-to-operate control panel.
- Over 80 piezo tips to choose from for a variety of clinical applications.
Thursday, September 4, 2014
See What’s “New” in Dentistry Today!
Spokane, WA – August 26, 2014 – Aurum Ceramic Dental Laboratories, and its affiliated Aurum Group companies (Aurum Ceramic @ LVI and Space Maintainers – Pacific Northwest), are pleased to announce the launch of its re-designed, fully-featured website at www.aurumgroup.com. The new site has extensive content, both on-line and available for download, including full details on what’s new in dentistry today: new products, new techniques, new on-line tools and new Continuing Education opportunities.
The Aurum Ceramic website is designed to assist dental professionals in comparing and applying the latest alternatives in state-of-the-art dentistry today, including the rapidly expanding areas of implantology and digital dentistry. The site features robust Brochure and Technical Information download sections for dentists, laboratory technicians and patients. Along with a more contemporary design, changes have been made to the site-wide navigation to help clinicians, and their extended teams, find the information and materials they need faster, both on-line and via mobile media. The site reflects Aurum Ceramic’s, and the Aurum Group’s, commitment to providing Complete Root-To-ToothTM Solutions in all aspects of the dental industry.
To visit the new site, visit www.aurumgroup.com.
About Aurum Ceramic Dental Laboratories
Aurum Ceramic (www.aurumgroup.com) specializes in Comprehensive Aesthetic and Implant Dentistry. As a leader in state-of-the-art dentistry, we are committed to setting the platinum standard in laboratory services and outstanding results. Aurum Ceramic has always been committed to supporting dentistry with not only the most technologically advanced restorative materials and techniques available but also in terms of research, education and program assistance. We are proud to be a Platinum Lab Partner at LVI Global (The Las Vegas Institute of Advanced Dental Studies). Aurum Ceramic works closely with the Pacific Implant Institute, Common Sense Dentistry (Dr. Louis Malcmacher) and PTC; is a Corporate Gold Member of AACD; and are supporters of Oral Health America and many other foundations and initiatives.
Wednesday, September 3, 2014
Tuesday, September 2, 2014
AUG 21 (WASHINGTON)–On Friday the U. S. Drug Enforcement Administration (DEA) will publish in the Federal Register the Final Rule moving hydrocodone combination products (HCPs) from Schedule III to the more-restrictive Schedule II, as recommended by the Assistant Secretary for Health of the U.S. Department of Health and Human Services (HHS) and as supported by the DEA’s own evaluation of relevant data. The Federal Register has made the Final Rule available for preview on its website today at http://go.usa.gov/mc8d.
This Final Rule imposes the regulatory controls and sanctions applicable to Schedule II substances on those who handle or propose to handle HCPs. It goes into effect in 45 days.
The Controlled Substances Act (CSA) places substances with accepted medical uses into one of four schedules, with the substances with the highest potential for harm and abuse being placed in Schedule II, and substances with progressively less potential for harm and abuse being placed in Schedules III through V. (Schedule I is reserved for those controlled substances with no currently accepted medical use and lack of accepted safety for use.) HCPs are drugs that contain both hydrocodone, which by itself is a Schedule II drug, and specified amounts of other substances, such as acetaminophen or aspirin.
“Almost seven million Americans abuse controlled-substance prescription medications, including opioid painkillers, resulting in more deaths from prescription drug overdoses than auto accidents,” said DEA Administrator Michele Leonhart, “Today’s action recognizes that these products are some of the most addictive and potentially dangerous prescription medications available.”
When Congress passed the CSA in 1970, it placed HCPs in Schedule III even though it had placed hydrocodone itself in Schedule II. The current analysis of HCPs by HHS and the DEA shows they have a high potential for abuse, and abuse may lead to severe psychological or physical dependence. Adding nonnarcotic substances like acetaminophen to hydrocodone does not diminish its abuse potential. The many findings by the DEA and HHS and the data that support these findings are presented in detail in the Final Rule on the website. Data and surveys from multiple federal and non-federal agencies show the extent of abuse of HCPs. For example, Monitoring the Future surveys of 8th, 10th, and 12th graders from 2002 to 2011 found that twice as many high school seniors used Vicodin®, an HCP, nonmedically as used OxyContin®, a Schedule II substance, which is more tightly controlled.
In general, substances placed under the control of the CSA since it was passed by Congress in 1970 are scheduled or rescheduled by the DEA, as required by the CSA and its implementing regulations, found in Title 21 of the Code of Federal Regulations. Scheduling or rescheduling of a substance can be initiated by the DEA, by the HHS Assistant Secretary of Health, or on the petition of any interested party. (Detailed information on the scheduling and rescheduling process can be found beginning on page 8 of Drugs of Abuse on the DEA’s website at http://www.justice.gov/dea/pr/multimedia-library/publications/drug_of_abuse.pdf.)
The rescheduling of HCPs was initiated by a petition from a physician in 1999. The DEA submitted a request to HHS for a scientific and medical evaluation of HCPs and a scheduling recommendation. In 2013, the U. S. Food and Drug Administration held a public Advisory Committee meeting on the matter, and the committee voted to recommend rescheduling HCPs from Schedule III to Schedule II by a vote of 19 to 10. Consistent with the outcome of that vote, in December of 2013 HHS sent such a recommendation to the DEA. Two months later, on February 27, the DEA informed Americans of its intent to move HCPs from Schedule III to Schedule II by publishing a Notice of Proposed Rulemaking in the Federal Register, outlining its rationale and the proposed changes in detail and soliciting public comments on the proposal, of which almost 600 were received. A small majority of the commenters supported the proposed change.